NEW YORK (GenomeWeb News) – Danaher today said that revenues in the third quarter were down a fraction of 1 percent year over year as the company missed the consensus Wall Street estimate on the top and bottom line.

For the three months ended Sept. 28, revenues totaled $4.42 billion, compared to $4.45 billion a year ago, and short of the average analyst estimate of $4.51 billion.

Danaher said that core revenues grew 1 percent year over year while acquisitions added 1.5 percent to growth. The impact of currency translations shrank revenues by 3 percent, however.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.